Natural products (NPs) are a treasure trove of drug discovery, yet their structural complexity and extreme data scarcity critically hinder AI-driven exploration. To address this challenge, we present MSformer, a transformer-based architecture that bridges this gap by leveraging molecule fragments to systematically encode NP chemical space. These fragments were generated by a mass spectrometry-inspired fragmentation algorithm, termed meta-structures. Unlike chemical models pretrained on comprehensive molecule databases, MSformer is totally pretrained on very limited NP data set by deconstructing 400,000 NPs into 234 million meta-structures. This design enables MSformer to capture the structural richness and drug-like relevance of NPs. Evaluated on 14 tasks across MoleculeNet and the Therapeutics Data Commons data sets, MSformer outperforms state-of-the-art models, demonstrating superior generalizability in property prediction. The abundant meta-structures enable MSformer hierarchical interpretability that reveals task-specific structural determinants and successfully deconstructing approved drugs into bioactive fragments. By integrating domain knowledge with deep learning, MSformer establishes a transformative paradigm for NP-based drug discovery, offering a scalable framework to navigate nature's underexplored chemical repertoire and accelerate the identification of bioactive candidates.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: